|
KMID : 1101820180060020046
|
|
Journal of Breast Disease
2018 Volume.6 No. 2 p.46 ~ p.51
|
|
|
Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer
|
|
Kim Sang-Hee
Choi Ji-Hye
Park Chan-Sub
Kim Hyun-Ah
Noh Woo-Chul
Seong Min-Ki
|
|
|
Abstract
|
|
|
Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC.
Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy.
Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity.
Conclusions: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.
|
|
|
KEYWORD
|
|
|
Aromatase inhibitors, Breast neoplasms, Gonadotropin-releasing hormone, Goserelin, Premenopause
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|